List of Excipients in Branded Drug CEREBYX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	CEREBYX	fosphenytoin sodium	0069-5474	HYDROCHLORIC ACID
Pfizer Laboratories Div Pfizer Inc	CEREBYX	fosphenytoin sodium	0069-5474	SODIUM HYDROXIDE
Pfizer Laboratories Div Pfizer Inc	CEREBYX	fosphenytoin sodium	0069-5474	TROMETHAMINE
Pfizer Laboratories Div Pfizer Inc	CEREBYX	fosphenytoin sodium	0069-5474	WATER
Pfizer Laboratories Div Pfizer Inc	CEREBYX	fosphenytoin sodium	0069-6001	HYDROCHLORIC ACID
Pfizer Laboratories Div Pfizer Inc	CEREBYX	fosphenytoin sodium	0069-6001	SODIUM HYDROXIDE
Pfizer Laboratories Div Pfizer Inc	CEREBYX	fosphenytoin sodium	0069-6001	TROMETHAMINE

CEREBYX Excipient Strategy, Patent Position, and Commercial Opportunities for Fosphenytoin Sodium Injection

Last updated: September 25, 2026

CEREBYX is the branded injectable form of fosphenytoin sodium, a water-soluble prodrug of phenytoin used for urgent seizure control and short-term replacement therapy. Its commercial value is driven less by active-ingredient exclusivity than by injectable presentation, hospital supply reliability, admixture stability, administration safety, and product differentiation through excipient and container design.

The core CEREBYX composition is relatively simple: fosphenytoin sodium, tromethamine buffer, water for injection, and pH-adjusting agents. The main formulation opportunity is not a new therapeutic mechanism. It is a better parenteral product with improved ready-to-use handling, longer in-use stability, lower preparation burden, fewer concentration errors, and strong compatibility data.

What is CEREBYX and how does its formulation work?

CEREBYX contains fosphenytoin sodium, expressed as phenytoin equivalents. Fosphenytoin is converted in vivo to phenytoin by endogenous phosphatases. The prodrug was developed to overcome the poor aqueous solubility and formulation limitations of injectable phenytoin.

Product attribute	CEREBYX profile
Active ingredient	Fosphenytoin sodium
Pharmacologic conversion	Hydrolysis to phenytoin
Dosage form	Sterile intravenous or intramuscular injection
Strength	75 mg phenytoin equivalents per mL
Primary clinical use	Status epilepticus and short-term parenteral substitution
Original sponsor	Parke-Davis, later part of Pfizer
FDA approval	1996
Administration metric	Doses expressed in phenytoin equivalents, or PE
Current competitive class	Generic fosphenytoin sodium injection
Biosimilar relevance	None; fosphenytoin is a chemically synthesized small molecule

The formulation uses tromethamine to support an alkaline aqueous environment and maintain solubility. The product is supplied in single-dose vials and is diluted before intravenous infusion when required by the administration setting. The FDA label identifies water for injection and pH-adjusting ingredients as formulation components.[1]

What excipients are used in CEREBYX?

The principal excipient system consists of tromethamine, water for injection, and pH-control agents. The formulation does not rely on the propylene glycol and ethanol vehicle historically associated with injectable phenytoin sodium products.

Excipient or component	Function	Commercial significance
Tromethamine	Buffering and pH control	Supports aqueous solubility and product stability
Water for injection	Parenteral vehicle	Requires control of bioburden, endotoxin, and particulate matter
Hydrochloric acid and/or sodium hydroxide	pH adjustment	Controls solubility, stability, and container compatibility
Container-closure system	Product protection	Affects extractables, leachables, adsorption, and shelf life

The absence of organic cosolvents is a major product attribute. Injectable phenytoin has historically presented formulation and administration concerns related to alkaline pH, precipitation, local tissue injury, and incompatibility. Fosphenytoin was designed to provide a more practical parenteral alternative, although it retains risks associated with rapid administration, hypotension, cardiac effects, and dosing errors.[1]

An excipient change must preserve several linked properties:

• Fosphenytoin solubility across the labeled concentration range.
• Chemical stability during storage and dilution.
• Conversion kinetics to phenytoin.
• Low particulate burden.
• Low risk of precipitation after dilution.
• Compatibility with intravenous tubing and infusion devices.
• Acceptable osmolality and pH for the intended route.
• Sterility and container-closure integrity.

What excipient strategy is most attractive for a CEREBYX competitor?

The strongest strategy is a conservative, hospital-oriented formulation that improves workflow without changing the clinical dose or route.

Ready-to-use diluted presentations

A ready-to-use bag or syringe could eliminate bedside dilution. Current vial-based products require dose calculation, withdrawal, dilution, labeling, and administration. A premixed product could reduce compounding steps and lower the risk of PE-to-milligram conversion errors.

Potential presentations include:

Presentation	Target setting	Commercial rationale
Single-dose prefilled syringe	Emergency department, intensive care	Fast administration and lower preparation burden
Small-volume infusion bag	Emergency and inpatient use	Eliminates bedside dilution
Standardized pediatric syringe	Pediatric emergency care	Reduces weight-based dosing and concentration errors
Pharmacy bulk package	Institutional pharmacy	Supports controlled preparation and inventory efficiency
Unit-dose vial with integrated transfer device	Hospitals with centralized pharmacy	Improves handling without major regulatory change

A ready-to-use product may require a new drug application, a 505(b)(2) application, or another FDA pathway depending on the extent of formulation, presentation, labeling, and clinical reliance on the reference product. A conventional generic vial is more likely to pursue an abbreviated new drug application, but a new container, concentration, or premixed format may create additional FDA requirements.

Improved in-use stability

The label permits dilution in compatible infusion solutions under specified conditions. A competing product could seek longer validated in-use stability, broader temperature tolerance, or more extensive compatibility data. This would matter for emergency carts, transport, operating rooms, and automated dispensing systems.

Stability work should examine:

• Unopened shelf life.
• Diluted stability in 0.9% sodium chloride.
• Diluted stability in 5% dextrose.
• Stability in syringes and infusion bags.
• Light exposure.
• Agitation and transport.
• Freeze-thaw stress.
• High-temperature excursions.
• Adsorption to plastic surfaces.
• Precipitation after dilution.
• Particulate formation.
• Container-closure extractables and leachables.

A longer in-use period can create operational value, but the claim must be supported by validated chemical, physical, microbiological, and container-compatibility data.

Low-particulate and low-leachable design

Hospital buyers increasingly evaluate injectable products for particulate control and packaging quality. A competitor could differentiate through:

• Improved glass vial selection.
• Low-silicone or silicone-controlled syringes.
• Low-extractable elastomer stoppers.
• Reduced tungsten-related glass defects.
• Better terminal sterilization or aseptic-processing controls.
• Transparent compatibility data for common administration sets.

These attributes are rarely sufficient as stand-alone patent claims. They can support procurement, quality agreements, and hospital formulary adoption.

What formulation patents could protect a new fosphenytoin product?

The original active-ingredient and prodrug protection for fosphenytoin is historical and no longer represents a meaningful barrier to generic entry. Commercial protection now would more likely arise from a specific formulation, dosage form, device, manufacturing process, or method of use.

Potential patentable subject matter includes:

1. Premixed injectable compositions. Claims could cover fosphenytoin concentration, buffer range, osmolality, dilution medium, and stability period.

2. Prefilled syringes. Claims could cover syringe materials, stopper design, fill volume, headspace, and prevention of adsorption or precipitation.

3. Container-closure systems. A product could protect a vial, syringe, bag, or transfer device selected for low extractables and long-term stability.

4. Extended in-use stability. Claims could cover compositions that remain within specification after dilution and storage under defined conditions.

5. Pediatric dosing systems. A device or presentation that links weight-based dosing to a standardized fosphenytoin concentration could support device or combination-product claims.

6. Manufacturing processes. Process claims could cover control of pH adjustment, mixing order, filtration, sterilization, filling, or impurity reduction.

7. Administration methods. A method patent could cover use of a specified concentration, infusion rate, or device configuration. Such claims would need to avoid overlap with the FDA label and existing clinical practice.

The strongest patent position would combine composition claims with container and process claims. A formulation patent limited to a routine buffer adjustment would face greater validity risk than claims tied to an unexpected stability, compatibility, or safety result.

When does CEREBYX lose exclusivity and what is the Orange Book status?

CEREBYX's original regulatory and active-ingredient exclusivity periods have expired. Generic fosphenytoin sodium injection products are available, and the market is not protected by an active biologic exclusivity period.

Exclusivity category	CEREBYX status
New chemical entity exclusivity	Expired
Original composition patent protection	Expired or no longer commercially controlling
Pediatric exclusivity	Expired
Orphan-drug exclusivity	Not the principal protection for the product
Biosimilar exclusivity	Not applicable
Generic competition	Established
Current protection focus	Formulation, device, supply, and contracting advantages

CEREBYX is a small-molecule drug, so biosimilar rules do not apply. Generic applicants generally rely on the reference product's safety and efficacy findings through the ANDA pathway, subject to applicable sameness, bioequivalence, quality, and labeling requirements.[2]

The practical Orange Book question is whether any unexpired, relevant patents remain listed against the specific reference product and whether those patents cover the marketed dosage form or method of use. Historical patent protection for fosphenytoin does not by itself establish a current barrier. A live Orange Book listing, if any, must be assessed by patent number, expiration date, listed claim scope, and the product's current FDA approval status.[3]

Which companies compete with CEREBYX?

Competition comes from generic fosphenytoin injection manufacturers and from substitute products, particularly injectable phenytoin and intravenous levetiracetam.

Competitive category	Examples	Competitive effect
Brand fosphenytoin	CEREBYX	Reference product and clinical familiarity
Generic fosphenytoin	Multiple FDA-approved suppliers	Price competition and shortage substitution
Injectable phenytoin	Generic phenytoin sodium injection	Lower-cost clinical alternative with greater formulation limitations
IV levetiracetam	Multiple suppliers	Alternative seizure-management product
Valproate injection	Multiple suppliers	Alternative for selected acute seizure scenarios
Midazolam and other rescue agents	Multiple suppliers	Compete in acute seizure protocols

Hospitals may prefer fosphenytoin when rapid parenteral therapy is required and the institution wants to avoid some of the handling and infusion issues associated with phenytoin. Price, availability, formulary protocols, and shortage conditions determine the final product choice.

A new fosphenytoin product must compete against an established generic market rather than against CEREBYX alone. A lower price may secure volume, but a differentiated presentation can support higher net pricing if it reduces pharmacy labor, administration time, waste, or medication-error risk.

What commercial opportunities exist for a new fosphenytoin formulation?

The most practical opportunities are operational.

Hospital emergency-use products

Emergency departments and intensive-care units value products that reduce preparation time. A prefilled syringe or premixed bag could be positioned for:

• Status epilepticus protocols.
• Emergency medication carts.
• Intensive-care admission orders.
• Operating-room seizure management.
• Interfacility transport.
• Pediatric emergency departments.

Pediatric dosing

Pediatric use creates a dosing and presentation opportunity because dosing is weight-based and often expressed in mg PE/kg. A standardized low-volume syringe with clear PE labeling could reduce conversion mistakes.

The product must avoid confusing phenytoin-equivalent dose with fosphenytoin sodium mass. Labeling, syringe graduations, barcode configuration, and electronic medication-record compatibility are central commercial features.

Supply-chain resilience

Fosphenytoin has a relatively concentrated hospital market. A supplier that maintains reliable inventory, offers multiple vial or syringe sizes, and provides shortage-resistant manufacturing can win contracts even without the lowest unit price.

Commercial differentiation can include:

• Dual-source active pharmaceutical ingredient strategy.
• Domestic or regional fill-finish capacity.
• Multi-size packaging.
• Stable allocation commitments.
• Hospital-specific inventory programs.
• Automated dispensing cabinet compatibility.
• Barcoded unit-dose packaging.

Licensing opportunities

A formulation developer could license:

• A ready-to-use fosphenytoin presentation to an established injectable manufacturer.
• A prefilled syringe platform to a contract development and manufacturing organization.
• A low-extractable container system to a generic supplier.
• A pediatric dosing device to a hospital-focused pharmaceutical company.
• A stability package that supports a 505(b)(2) product.

A license is more attractive when the technology provides measurable savings or a defensible regulatory position. A generic manufacturer may prefer a supply agreement or co-development deal if the product can be filed through an abbreviated pathway.

How strong is the patent estate for a new CEREBYX formulation?

A new formulation can have a moderate patent position, but the commercial strength depends on claim breadth and design-around risk.

Asset	Expected strength	Main vulnerability
Core fosphenytoin composition	Low for new entrants	Historical protection expired
New buffer system	Low to moderate	Obviousness and routine formulation optimization
Premixed formulation	Moderate	Prior-art combinations and design-around
Prefilled syringe system	Moderate	Device substitution and narrow claim scope
Extended stability claim	Moderate to strong if unexpected	Need for robust comparative data
Specialized pediatric device	Moderate	Possible separation of drug and device claims
Manufacturing impurity-control process	Moderate	Process verification and alternative processes
Proprietary container-closure combination	Moderate	Supplier substitution and functional claiming limits

The best protection is likely to come from a portfolio rather than a single patent. A practical filing program would cover the composition, presentation, container, manufacturing method, and use conditions separately. Trade-secret protection can supplement patents for process parameters, filling conditions, and impurity-control methods.

What litigation and Paragraph IV risks affect fosphenytoin?

The principal Paragraph IV risk relates to any unexpired patent listed against the reference product. Because CEREBYX's foundational protection is historical and generic products are already marketed, litigation risk is likely to center on later formulation, device, or method patents rather than the original prodrug invention.

A new entrant should evaluate:

• Orange Book-listed patents for the reference NDA.
• Patent-term adjustment and expiration dates.
• Patent certifications filed by generic applicants.
• Any FDA delisting disputes.
• ANDA litigation under the Hatch-Waxman Act.
• Label carve-outs for method-of-use patents.
• Settlement agreements involving launch timing.
• Paragraph IV notices and 30-month stays.

No biosimilar litigation framework applies. A fosphenytoin applicant would face small-molecule Hatch-Waxman procedures, not the Biologics Price Competition and Innovation Act pathway.

A formulation patent owner can seek a 30-month stay after receiving a Paragraph IV notice, subject to statutory requirements and timing. A patent that covers only a narrow presentation may not block a generic vial applicant if the generic can use a noninfringing presentation.

How does CEREBYX compare with injectable phenytoin?

Fosphenytoin and phenytoin compete clinically but have different formulation profiles.

Attribute	Fosphenytoin	Phenytoin sodium
Aqueous solubility	Higher as a prodrug	Limited
Organic cosolvent dependence	Lower	Historically significant
Administration	IV or IM	Primarily IV in acute settings
Dose expression	Phenytoin equivalents	Phenytoin sodium amount
Conversion requirement	Yes	No
Preparation complexity	Lower in standard use	Higher in many settings
Commercial differentiation	Presentation, stability, dosing tools	Price and availability
Main formulation opportunity	Ready-to-use and pediatric formats	Improved compatibility and administration systems

Fosphenytoin has a stronger platform for a modern parenteral product because its aqueous formulation is more adaptable to premixed formats. The active ingredient remains vulnerable to generic price competition, so commercial value must come from delivery and workflow.

What regulatory path applies to a new excipient-based CEREBYX product?

A conventional generic fosphenytoin injection can generally pursue an ANDA if it matches the reference product in active ingredient, dosage form, route, strength, and relevant pharmaceutical characteristics. A materially different excipient system may still be possible, but the applicant must establish that the change does not create a safety or efficacy difference.

A new premixed bag, prefilled syringe, pediatric concentration, or device-integrated product may require a different regulatory strategy. The applicable pathway depends on whether the product remains pharmaceutically equivalent, whether the presentation changes clinical use, and whether additional clinical or human-factors evidence is required.

FDA review will focus on:

• Sterility assurance.
• Endotoxin control.
• Particulate matter.
• Extractables and leachables.
• Stability and degradation products.
• In-use and diluted compatibility.
• Dose uniformity.
• Container-closure integrity.
• Administration-device performance.
• Label clarity for PE dosing.

The FDA label's warnings on dosing, infusion rate, cardiovascular effects, and conversion to phenytoin remain central to any reformulated product.[1]

Key Takeaways

• CEREBYX is an off-patent small-molecule injectable based on fosphenytoin sodium.
• Its core excipient system uses tromethamine, water for injection, and pH-adjusting agents.
• The main commercial opportunity is a better hospital presentation, not a new active ingredient.
• Ready-to-use bags, prefilled syringes, and pediatric dosing formats have the clearest differentiation potential.
• Extended in-use stability, container compatibility, low particulate burden, and supply reliability can support hospital contracting.
• New patent value would likely come from formulation, device, container, manufacturing, or administration claims.
• Biosimilar competition is irrelevant because fosphenytoin is a chemically synthesized small molecule.
• Paragraph IV risk depends on any live Orange Book-listed patents, particularly later formulation or method-of-use patents.
• The strongest business case combines a defensible formulation portfolio with a lower-error, lower-workflow-burden product.

FAQs

Is CEREBYX the same as phenytoin?

No. CEREBYX contains fosphenytoin, a prodrug that is converted to phenytoin after administration. Doses for CEREBYX are expressed as phenytoin equivalents.

Does CEREBYX contain propylene glycol?

The CEREBYX formulation is not based on the traditional propylene glycol and ethanol vehicle used in injectable phenytoin formulations. Its listed formulation uses an aqueous vehicle with tromethamine and pH-adjusting agents.[1]

Can a company patent a new fosphenytoin excipient system?

Yes, but patent strength depends on whether the composition provides a non-obvious and measurable benefit, such as improved stability, compatibility, reduced precipitation, or a commercially meaningful ready-to-use presentation.

Is a premixed fosphenytoin product likely to receive higher pricing?

It can receive a price premium if it reduces pharmacy preparation, medication errors, product waste, or administration time. The premium must be supported by procurement savings and operational evidence.

Are generic fosphenytoin products subject to biosimilar substitution rules?

No. Fosphenytoin is a small-molecule drug. Generic substitution and approval are governed primarily by the ANDA and Hatch-Waxman framework, not the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2023). Cerebyx (fosphenytoin sodium) injection prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2018). Drug products marketed in the United States that contain fosphenytoin sodium. Drugs@FDA database. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.